ESI gets rights to diabetes technology
Thursday, 19 December, 2002
Singapore-based stem cell company ES Cell International (ESI) has acquired patent rights to technology relating to the transformation of stem cells into insulin-producing cells from US company Curis.
Under the terms of the agreement, ESI will be responsible for continuing the development and testing of Curis' diabetes stem cell technologies.
According to Robert Klupacs, CEO of ESI, the acquisition will enhance ESI's diabetes cell therapy program and complements other technology the company has licensed in for the program.
"Accessing both Curis' world-class technologies and research capabilities will significantly accelerate our ability to bring cell-based therapies for diabetes to the clinic," Klupacs said in a statement.
ESI is developing therapeutic technologies for the treatment of diabetes and Parkinson's disease using embryonic and adult stem cells.
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
Portable point-of-care test detects four common STIs in under an hour
Australian researchers have developed a portable point-of-care test that detects four common...
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
